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The lateral nucleus of the amygdala (LA) is a key element in the neural circuit subserving
Pavlovian fear-conditioning, an animal model of fear and anxiety. Most studies have
focused on the role of the LA in fear acquisition and extinction, i.e., how neural plasticity
results from changing contingencies between a neutral conditioned stimulus (CS) (e.g.,
a tone) and an aversive unconditioned stimulus (US) (e.g., a shock). However, outside of
the lab, fear-memories are often the result of repeated and unpredictable experiences.
Examples include domestic violence, child abuse or combat. To better understand the role
of the LA in the expression of fear resulting from repeated and uncertain reinforcement,
rats experienced a 30% partial reinforcement (PR) fear-conditioning schedule four days
a week for four weeks. Rats reached asymptotic levels of conditioned-fear expression
after the first week. We then manipulated LA activity with drug (or vehicle) (VEH)
infusions once a week, for the next three weeks, before the training session. LA
infusions of muscimol (MUSC), a GABA-A agonist that inhibits neural activity, reduced
CS evoked fear-behavior to pre-conditioning levels. LA infusions of pentagastrin (PENT),
a cholecystokinin-2 (CCK) agonist that increases neural excitability, resulted in CS-evoked
fear-behavior that continued past the offset of the CS. This suggests that neural activity in
the LA is required for the retrieval of fear memories that stem from repeated and uncertain
reinforcement, and that CCK signaling in the LA plays a role in the recovery from fear after
the removal of the fear-evoking stimulus.
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INTRODUCTION
The lateral nucleus of the amygdala (LA) is a key component
of the neural circuitry sub-serving Pavlovian fear-conditioning
(Maren and Quirk, 2004). Fear-conditioning is a behavioral pro-
cedure involving the pairing of a neutral conditioned stimulus
(CS) with an aversive unconditioned stimulus (US). Following
CS-US pairing, the CS comes to elicit defensive fear-behaviors
(Blanchard et al., 1993). Much progress has been made in under-
standing the role of the amygdala in learning and consolida-
tion of the CS-US association (Lamprecht and LeDoux, 2004;
Rodrigues et al., 2004; Schafe et al., 2005; Pape and Pare, 2010;
Johansen et al., 2011). These studies generally use continuous
reinforcement, where every presentation of the CS in acquisi-
tion is followed by the presentation of a US. However, it is also
important to understand the mechanisms for the retrieval of fear-
memories that are the result of partial reinforcement (PR), where
the CS probabilistically predicts the US. This is especially true in
a clinical context—abused children and soldiers can suffer from
post-traumatic stress disorder (PTSD) that stems from repeated
probabilistic associations (Foa and Meadows, 1997).
The physiological and behavioral consequences of partial rein-
forcement in fear-conditioning depend on a variety of factors.
Probabilistic CS-US associations can be more stressful than
predictable CS-US associations (McGuire et al., 2010). The uncer-
tainty of the outcome (for example, waiting for the results of a
biopsy with a 30% chance of being positive) can result in high
levels of anxiety (Poole et al., 1999; Thompson and Hepburn,
2003), which may involve distinct neural mechanisms than those
involved in certain CS-US associations (Yu and Dayan, 2005).
Partial reinforcement can also result in learning that is resistant
to extinction, a phenomena known as the “partial reinforce-
ment extinction effect” (Wagner et al., 1967). Negative mood,
depression, or stress can bias subjects to interpret ambiguous
cues as more aversive (Msetfi et al., 2005; Tsetsenis et al., 2007).
Human studies of fear-conditioning commonly use partial rein-
forcement and have demonstrated that the amygdala activity
correlates with behavioral measures of fear during this paradigm
(LaBar et al., 1998; Delgado et al., 2008; Dunsmoor et al., 2008),
which suggests that the amygdala plays a similar role in learn-
ing and retrieval of partially reinforced CS-US associations as
it does in continuously reinforced CS-US associations. Despite
extensive behavioral and neuroimaging studies investigating the
effects of partial reinforcement in fear-conditioning, there are rel-
atively few studies of the neural bases of these phenomena in
animals. This is somewhat surprising given that fear-conditioning
has been a tremendously successful translational tool for treating
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human fear disorders (Ressler et al., 2004; Phelps et al., 2004;
Davis et al., 2006; Bush et al., 2007; Quirk et al., 2007; De¸biec et al.,
2011), which likely dependmore on probabilistic than continuous
reinforcement.
Here we investigated the relationship between neural activity
in the LA and fear-expression evoked by repeated exposure to a
CS partially reinforced with footshock. We designed a lick sup-
pression task suited to examining within-subject pharmacological
manipulations that could result in either increased or decreased
fear-expression and also the expression of fear both during and
after the CS.
We chose to use two drugs to bidirectionally modulate LA
activity in this task: muscimol (MUSC), a GABA-A agonist,
and pentagastrin (PENT), a CCK2 agonist. We hypothesized
that MUSC would reduce conditioned fear-expression and PENT
would increase conditioned fear-expression. Muscimol function-
ally inactivates neurons by binding to and activating GABA-A
receptors. Previous studies have demonstrated that muscimol
inactivation of the LA blocks the expression of fear in typical fear
conditioning experiments where training consists of a few reli-
able CS-US pairings, and testing is done within 24 h of training
(Wilensky et al., 2000; Maren, 2001; Blair et al., 2005).
Pentagastrin is an agonist of the cholecystokinin-2 (CCK2)
receptor, a G-protein coupled receptor which has been shown
to cause an increase in the excitability of neurons in the baso-
lateral amygdala via activation of a non-specific cation channel
(Meis et al., 2007; Chung andMoore, 2009). Pentagastrin injected
intravenously causes panic attacks (Bradwejn et al., 1990; Geraci
et al., 2002), which has generated interest in the role of CCK in
anxiety. In fear-potentiated startle, intra-amygdala blockade of
CCK2 receptors blocks the anxiogenic effect of systemic PENT
(Frankland et al., 1997), suggesting that CCK2 binding in the
amygdala may be responsible for the panic inducing effects of
CCK in humans. Aside from the pre-clinical interest in the contri-
bution of the CCK system to the retrieval of chronic probabilistic
fear-memory, we used PENT in this study because local infusion
of the drug into the LA of rats potentiated acoustic startle without
affecting baseline activity (Frankland et al., 1997). By definition,
it is necessary to measure lick suppression against a baseline level
of licking activity, so we avoided drugs that have strong effects on
baseline behavior, including GABA-A antagonists like picrotoxin
and bicuculline, which are known to have general anxiogenic
and epileptogenic effects (Gean and Shinnick-Gallagher, 1987;
Sanders and Shekhar, 1995; Chu and Lin, 1996).
MATERIALS AND METHODS
Subjects. Subjects were adult male Sprague Dawley rats (Hilltop,
PA) weighing 350–400 g. They were housed individually in plastic
Nalgene cages and maintained on a 12 h light/dark cycle. Water
was provided freely throughout the experiment. After recovery
from surgery (see below) they were maintained on a restricted
diet until they reached 90% of their original body weight. All pro-
cedures were in accordance with Public Health Service guidelines
and were approved by the animal use committee of New York
University. Ten rats underwent surgery. Two animals never met
criteria for pre-habituation (described below) and one animal was
excluded due to an erroneous cannula placement.
Surgery. Under ketamine (100mg/kg, i.p.), xylazine (6.0mg/kg,
i.p.), and medetomidine (0.5mg/kg, i.p.) anesthesia, rats were
implanted bilaterally with 22-gauge stainless steel guide can-
nulae that terminated 1.5mm above the target location in the
LA. The target location coordinates, taken from Paxinos and
Watson (2004), were +5.7 anteroposterior, ±5.3 mediolateral,
and+2.0mm dorsoventral with reference to inter-aural zero. The
guide cannulae were anchored to the skull with dental cement.
A 28-gauge dummy cannula was inserted into each guide can-
nula to prevent clogging, and dummy cannulae were changed
once per week. After surgery, rats were given buprenorphine HCl
(0.2mg/kg, s.c.) as an analgesic. Rats were given at least 5 d to
recover from surgery before the beginning of behavioral training.
Drugs. The vehicle (VEH) was 50millimolar sodium bicarbon-
ate in physiological saline (0.9% NaCl). The PENT infusion was
0.375μg of pentagastrin (B1636, Sigma-Aldrich) in 0.25μL of
VEH (Frankland et al., 1997). The MUSC infusion was 0.125μg
of muscimol (M1523, Sigma-Aldrich) in 0.25μL of physiological
saline (Wilensky et al., 2000).
Behavior. All behavior took place in a Plexiglas chamber with
dimensions 23 cm × 28 cm × 34 cm (Med-Associates, Inc.) with
a recessed lick spout enclosed in a sound and light attenuating
chamber during the rat’s light cycle. The CS was an auditory stim-
ulus made up of 20 pure tone pips. The frequency of each pip was
12 kHz and duration was 250ms. The interval between pip onsets
was 1 s. Thus, the total duration of the CS was 20 s. The US was a
brief footshock (0.5mA, 200ms) delivered 20 s after the onset of
the CS. Conditioned lick suppression was used as our measure of
fear and was quantified as a suppression ratio (Repa et al., 2001).
The suppression ratio was defined as (LPRE − LCS)/(LPRE + LCS)
where LPRE is the number of licks in the 20 s pre-CS period and
LCS is the number of licks in the 20 s CS period. Trials with no CS-
evoked suppression have a suppression ratio of zero. CS-evoked
suppression results in positive suppression ratios. Complete sup-
pression (no licking during the CS) results in a suppression
ratio of one. CS-evoked facilitation of licking results in negative
suppression ratios.
After recovery from surgery rats were pre-habituated to the
behavioral chamber where they were trained to lick for a sug-
ary orange drink (Kool-Aid®, Kraft Foods; 5 g/100mL water) to
maintain a constant level of activity against which suppression
could be reliably measured. This phase of training lasted 3–6 days.
By giving the rats extensive exposure to the context before con-
ditioning, we tried to minimize any contextual fear-conditioning
(Escobar et al., 2002). Once the rats licked consistently, the behav-
ioral training began (Figure 1). The experiment lasted five weeks.
The first week consisted of one habituation (HAB) session and an
initial training session the following day. For the habituation ses-
sion (HAB), rats were placed in the chamber for a 20 trial session
with an inter-trial interval of 1–4min. Each trial was a presenta-
tion of the CS. The next day rats returned to the chamber for a 20
trial session with a 30% CS-US contingency. This session resulted
in the initial formation of the CS-US association.
In the following weeks, each animal had one partial reinforce-
ment (PR) session per day for four days (Monday–Thursday).
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FIGURE 1 | Partial-reinforcement auditory fear-conditioning paradigm.
(A) Animals were pre-habituated (pre-HAB) to the behavioral apparatus and to
the orange drink. This continued until they reach a criterion of licking
consistently for 1 h. Habituation (HAB) consisted of 20 presentations of the
CS with no reinforcement. The next day partial reinforcement (PR)
fear-conditioning began. Each training session consisted of 20 presentation
of the CS with a 30% probability of the CS being followed by the US.
The first infusion was given after six days of PR. (B) The CS was
series of twenty 250ms, 12 kHz pure tone pips presented once per
second for 20 s. On 30% of trials a 200ms footshock US (0.5mA)
was given 20 s after the start of the CS (750ms after the end of the
last 12KHz pip). (C) Suppression ratio on non-drug training days
stabilized after an initial three days of training. Yellow arrows indicate
infusion days.
The first week (PR0) was four conditioning sessions with no
infusions. On the following weeks (PR1–3) the first three days
were conditioning days with no infusions and on the fourth
day (of weeks PR1–3) each animal received a bilateral intra-
LA infusion of either VEH, PENT, or MUSC, counterbalanced
across weeks 15min before the conditioning session. Specifically,
three rats received PENT, then MUSC, then VEH, two rats
received VEH, then PENT, then MUSC and two rats received
MUSC, then VEH, then PENT infusions in weeks PR1, PR2,
and PR3, respectively. As such, over the course of the exper-
iment each rat received all three infusions. Since the behav-
ior preceding each infusion day was not statistically different,
we present the effects of drug and VEH on suppression ratio
without adjusting for the activity during the preceding days.
The CS-US contingency was the same (30%) for infusion and
non-infusion days.
Intracranial infusions. Rats were held in the experimenter’s lap
while dummy cannulae were replaced with 28 gauge infusion
cannulae attached to 1.0μl Hamilton (Reno, NV) syringes via
polyethylene tubing. The infusion cannula extended 1.5mm
beyond the tip of the guide cannula directly into the target
location in the LA. The tubing was back-filled with sesame oil,
with a small air bubble separating the oil from the drug. Drugs
were infused bilaterally using an infusion pump, and cannu-
lae were left in place for an additional 2min after infusion to
allow diffusion of the drug away from the cannula tip before
dummy cannula replacement. A total amount of 0.25μl of drug
or VEH was infused into the LA bilaterally over 105 s. This vol-
ume was chosen on the basis of autoradiographic studies of the
spread of MUSC applied to the size and structure of the target
(Martin, 1991). Infusions preceded the behavioral session by
15min. The effects of MUSC have been shown to last for hours
(Edeline et al., 2002). We are unaware of studies that have directly
examined the duration of the effects of PENT, however, other
studies that have used PENT also waited 15–20min after infusion
before measuring significant behavior effects (Singh et al., 1991;
Frankland et al., 1997; Chhatwal et al., 2009).
Data analysis. All statistical analyzes were performed using
Statistica 7.0 (Statsoft; Tulsa, OK) or MATLAB (versions 6.5 or
later) (Mathworks; Natick, MA). For all analyzes, trials were
excluded if the rat did not lick during the pre-CS period for that
trial. For the ANOVA, trials for each rat were averaged and effects
were tested using a repeated measures design with each rat as
a case and the drug as the factor. For post-hoc tests comparing
specific groups we used multcompare (MATLAB) using Tukey’s
honestly significantly different test (HSD). For testing the cor-
relations between cannula placement and drug effects we used
corrcoef MATLAB.
Histology. To verify infusion cannula tip locations, rats were
anesthetized with an overdose of chloral hydrate (600mg/kg,
i.p.) and perfused transcardially with 10% buffered formalin.
The brains were post-fixed in 30% sucrose in formalin and
subsequently blocked, sectioned on a cryostat at 50μm, and
stained for Nissl using 0.5% cresyl violet. Sections were cover-
slipped with Permount (Fisher Scientific) and examined under
light microscopy for tip penetration into the amygdala (Figure 5).
The mean placement in mm with respect to inter-aural zero was
(mean± standard error): AP,−5.59 ± 0.04; ML, 5.19± 0.09; DV,
2.17 ± 0.10 (Paxinos and Watson, 2004).
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RESULTS
We trained male Sprague Dawley (Hilltop, PA) rats on a prob-
abilistic fear-conditioning paradigm: a 30% CS-US contingency,
against a background of appetitive motivation—access to a sweet
orange KoolAid© drink. This allowed us to measure both the
degree of lick suppression during the CS and also the time
to resume drinking after the CS. We chose 30% because a
pilot experiment of different contingencies (data not shown)
demonstrated that low CS-US contingencies (≤10%) resulted in
CS-evoked suppression that was too low and high CS-US contin-
gencies (100%) resulted in CS-evoked suppression that was too
high to be able to observe both increases and decreases in lick
suppression in response to manipulations of neural activity. We
measured lick suppression instead of freezing because the back-
ground of appetitive motivation enabled us to measure recovery
from fear, which may be an important factor for psychological
resilience (Charney, 2004; Yehuda et al., 2006; Bush et al., 2007).
After recuperating from bilateral implantation of cannulae
into the LA (5.7mm anterior, ±5.3mm lateral and 2mm dorsal
to inter-aural zero), rats were pre-habituated to the condition-
ing chamber and to the orange-flavored drink: they were simply
placed in the chamber and left there for 1 h per day until they
drank consistently over that period (Figure 1A). Then, there was
a single habituation (HAB) session (20 presentations of the CS)
followed by four days a week of partially reinforced condition-
ing (PR) for four weeks. As with the HAB phase, during PR
there were 20 presentations of the CS, but during PR there was
a 30% chance that the CS would be followed by a US (0.5mA,
200ms footshock). The first week was initial training with no
infusions. Starting in the second week, the first three days of
conditioning each week were no-infusion sessions, and on the
fourth day rats were infused with VEH, MUSC or PENT. Rats
received each infusion over the course of three weeks in a differ-
ent order. Conditioned lick suppression was detectable after the
first CS-US pairing and the suppression ratio during no-infusion
days was significantly greater than duringHAB (Figure 1C, paired
t-test, t6 = 6.67, p < 0.001). The suppression ratio was defined as
(LPRE − LCS)/(LPRE + LCS) where LPRE is the number of licks in
the 20 s pre-CS period and LCS is the number of licks in the 20 s
CS period. The CS-evoked suppression was not different during
the no-infusion days preceding VEH, MUSC or PENT infusion
days (ANOVA, p = 0.957). The order of infusion (VEH, MUSC,
PENT) was counter-balanced across animals.
The pharmacological manipulations in the LA had a sig-
nificant effect on suppression ratio [F(3, 18) = 7.03, p < 0.005;
Figure 2A]. Suppression ratio during MUSC sessions was signif-
icantly reduced relative to both VEH and PENT sessions (p <
0.05; Tukey’s HSD). Additionally, MUSC appeared to completely
abolish the effect of fear-conditioning, since there was no signif-
icant difference in the suppression ratio between the HAB and
MUSC sessions (p > 0.5, Tukey’s HSD). We did not find a sig-
nificant difference in suppression ratio between VEH and PENT
sessions (p > 0.5; Tukey’s HSD).
Since the suppression ratio is a function of CS and pre-CS lick-
ing, it is possible that the effect of MUSC on lick suppression
was due to changes in pre-CS licking. However, an analysis of
pre-CS licking in the four conditions shows no difference in the
amount of pre-CS licking between HAB, VEH,MUSC, and PENT
sessions [F(3, 18) = 1.58, p > 0.2; Figure 2B], indicating that the
drug effect on suppression ratio is attributable to a change in
licking during the CS.
It is possible (though unlikely) that MUSC infusions into the
LA attenuated lick suppression during the CS because of a sen-
sory or motor deficit that impaired infused rats from processing
sensory input or suppressing licking. To verify that the effect
of MUSC was specific to the CS-evoked suppression we exam-
ined whether the drug also prevented US-evoked suppression. To
quantify this we compared the latency to resume licking after
CS-US versus CS-alone trials. Figure 2C illustrates that MUSC
decreases the latency to resume licking after a CS [F(2, 10) =
21.3, p < 0.0005] but not a US [F(2, 10) = 0.24, p > 0.79] com-
pared to VEH and PENT (Figure 2C). This effect was robust: all
FIGURE 2 | Muscimol reduces expression of conditioned fear to
pre-conditioning levels. (A) Mean ± SE CS-evoked suppression ratio from
habituation (HAB), vehicle (VEH), muscimol (MUSC), and pentagastrin (PENT)
sessions. Muscimol significantly reduced levels of suppression compared to
vehicle and pentagastrin [Repeated Measures ANOVA, F(3,18) = 7.03,
p < 0.005]. (B) Mean ± SE number of licks during the 20 s pre-CS interval
from HAB, VEH, MUSC and PENT sessions. (n = 7). Drug-treatment did
not affect pre-CS lick levels [Repeated Measures ANOVA, F(3,18) = 1.58,
p > 0.2]. (C) Mean ± SE latency to lick (seconds) after a CS-alone
trial (CS) or a CS-US trial (CSUS) (n = 7). Muscimol reduces post-CS
suppression but does not eliminate post-US suppression. The VEH
was 50millimolar sodium bicarbonate in 0.25μL of physiological saline
(0.9% NaCl). The PENT infusion was 0.375μg of pentagastrin (B1636,
Sigma-Aldrich) in 0.25μL of vehicle. The MUSC infusion was 0.125μg
of muscimol (M1523, Sigma-Aldrich) in 0.25μL of physiological saline.
A total amount of 0.25μl of drug or vehicle was infused into the
LA bilaterally over 105 s. Infusions preceded the behavioral session
by 15m.
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FIGURE 3 | Pentagastrin impairs recovery from fear. (A) Histogram of
suppression ratio across trials for vehicle (gray), muscimol (blue), and
pentagastrin (brown) sessions. The suppression ratio distribution is
significantly bimodal for vehicle and pentagastrin (Hartigan’s Dip Test,
p < 0.001 for both vehicle and pentagastrin) but not for muscimol (Dip Test,
p > 0.7). In order to test recovery from fear we consider only the “high fear”
trials: trials where the suppression ratio was greater than 0.5. (B) Mean ± SE
number of licks during the 20 s post-CS interval from vehicle and pentagastrin
sessions after CS-alone trials where the suppression ratio was greater than
0.5. Post-CS licking after “high fear” trials, a proxy to recovery from fear, was
significantly lower in pentagastrin sessions than vehicle sessions [ANOVA,
F(1,6) = 8.05, p = 0.006].
rats in MUSC sessions took longer to resume licking on aver-
age after a CS-US trial than a CS trial. Moreover, if the MUSC
caused an auditory impairment such that the rats could not hear
the CS, we would expect that the mean suppression should be
zero. The suppression during the MUSC session was significantly
greater than zero (t-test, t6 = 4.51, p < 0.005).
While changes in suppression during the CS are one way to
detect an effect of a drug, the recovery from fear after the offset of
the CS could also provide important behavioral information. Our
proxy for recovery was the number of licks in the 20 s post-CS
period (excluding CS-US trials). Recovery from fear can only be
measured on trials where fear was expressed. We observed that the
suppression ratio across trials was bimodal for VEH and PENT
sessions (Hartigan’s Dip Test, p < 0.001 for both VEH and PENT,
Figure 3A). This indicates that, in these sessions, the conditioned
response on any given trial tended toward all or none: either the
animal “ignored” the CS on that trial or they suppressed licking
during most of the CS. This was not the case for MUSC sessions
(Dip Test, p > 0.7, Figure 3A) where the mode of the distribu-
tion of the suppression ratio was at 0, indicating that the CS was
“ignored” on most trials. For our analysis we considered a trial
to be “high fear” (and valid for measuring recovery) if the sup-
pression ratio was greater than 0.5 (Figure 3A), meaning there
was a 66% reduction in licking from the pre-CS period to the
CS period. To quantify the recovery from fear we analyzed the
number of post-CS licks for trials where the CS elicited suppres-
sion according to the “high fear” criteria. We found that PENT
infusions resulted in significantly increased maintenance of sup-
pression beyond the termination of the CS compared with VEH
[ANOVA, F(1, 6) = 8.05, p < 0.007]. This suggests that activation
of the CCK system in the LA results in fear-expression that persists
past the offset of the CS. Since MUSC reduced CS-evoked sup-
pression to pre-conditioning levels there were not enough “high
fear” trials to include these sessions in the statistical analysis.
Although the focus of these experiments was not to study
reconsolidation (Nader et al., 2000) of conditioned fear, we
examined the expression of fear on the first no-infusion day
FIGURE 4 | No observable effects on fear-expression on the no-infusion
day following drug treatment. We examined whether our
pharmacological manipulations of the LA (on Thursdays) affected the
following day of training (on Monday). Suppression Ratio on the first day
following each manipulation was not significantly different (ANOVA,
p > 0.8) suggesting that the drug treatments did not affect the
reconsolidation of the fear-memory.
following an infusion to test whether our manipulations might
have disrupted reconsolidation. This was especially relevant for
MUSC, where the manipulation reduced fear-expression to pre-
conditioning levels (Figure 2A). We did not find any reconsoli-
dation effect of drug infusion when tested on the following day
of training (Figure 4, ANOVA, p > 0.8). This is consistent with
the idea that MUSC in the LA blocks the retrieval of the fear-
memory that would be required to make it labile and susceptible
to disruption.
DISCUSSION
We modified the standard fear-conditioning paradigm to exam-
ine the role of the LA in the retrieval of a probabilistic CS-US
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association that evoked conditioned suppression which was stable
across multiple days (Figure 1C). We demonstrated that inacti-
vation of the LA with MUSC before a training session disrupts
CS-evoked suppression in that session even though the sub-
ject has experienced weeks of repeated exposure to the CS and
US. We also demonstrated that PENT infusions into the LA
resulted in enhanced maintenance of CS-evoked lick suppres-
sion beyond the offset of CS. This supports existing evidence
that LA neuronal activity is required for the retrieval of proba-
bilistic CS-US associations, and provides new evidence that LA
CCK2 receptor activation impairs the short-term recovery from
conditioned fear.
We initially predicted that MUSC and PENT would have
opposite effects on conditioned fear expression: that MUSC
would attenuate lick suppression and PENT would enhance it.
As predicted, MUSC attenuated lick suppression, consistent with
many previous studies that have demonstrated that MUSC inac-
tivation of the LA blocks the expression of fear (Wilensky et al.,
2000; Maren, 2001; Blair et al., 2005). The novelty of our finding
is that MUSC blocked fear-expression evoked by a partially rein-
forced CS that was experienced repeatedly for several weeks. The
previous studies only examined the effects of MUSC on a recently
learned 100% contingent CS-US association.
Pentagastrin did not increase lick suppression during the CS.
This lack of effect is unlikely to be a type II error (false negative)
because the mean suppression ratio in PENT sessions was actu-
ally lower than VEH, indicating that it was not a lack of statistical
power which resulted in this effect not reaching significance. It
may be possible to observe PENT-enhanced lick suppression dur-
ing the CS in a weaker conditioning paradigm: for example, a
conditioning paradigm that resulted in lower asymptotic level of
suppression (Figure 1C) either through a lower shock intensity or
lower CS-US contingency. Still, PENT had a significant effect on
behavior. It resulted in prolongedmaintenance of lick suppression
beyond the offset of the CS. This suggests that increasing excitabil-
ity of neurons in the LA attenuates an animal’s ability to recover
from fear.
CCK is produced by several distinct inter-neuronal popula-
tions in the basal and lateral nuclei of the amygdala (BLA) with
broad axonal arbors that terminate locally in the BLA but also
project medially and laterally, possibly to the central nuclei or
intercalated cell-masses of the amygdala (Jasnow et al., 2009). In
the rat, CCK2 receptor activation depolarizes inhibitory interneu-
rons (Chung and Moore, 2009). At first glance this seems contra-
dictory to our finding and to the general result that CCK2 receptor
agonism is anxiogenic (Singh et al., 1991; Frankland et al., 1997;
Rotzinger and Vaccarino, 2003). However, information flow from
the LA to the central amygdala outputs that control conditioned
suppression (Amorapanth et al., 1999; Ehrlich et al., 2009), is
controlled by an intricate circuit of excitatory and inhibitory neu-
rons in the basal, central and intercalated amygdala nuclei. It
may be that amygdalar excitatory CCK2 expressing interneurons
inhibit the inhibitory neurons that project to the central nucleus
to inhibit fear-expression. Thus excitation of these neurons may
result in disinhibition of central nucleus projection neurons that
drive conditioned suppression (See Figure 3 of Ehrlich et al.,
2009). This circuit has been proposed as a potential mechanism by
which extinction learning inhibits fear-expression. It has recently
been shown that CCK2 receptor activation can impair the extinc-
tion of fear-potentiated startle (Chhatwal et al., 2009) suggesting
that a common circuit, subject to modulation by CCK, plays a
role in the short-term recovery from fear and also extinction
learning.
SPREAD OF DRUGS
One concern with drug infusion studies is that drugs could spread
outside the target area. In this study, the target was the LA, but the
drug effects could have been due to receptor stimulation in adja-
cent structures like the basal or central nuclei of the amygdala.
However, several lines of evidence suggest that the behavioral
effects observed were due to modulation of LA activity, and not
an adjacent area. First, the histological placement of the injection
sites (Figure 5) did not correlate with suppression ratio (tested
Pearson correlation of right and left AP, ML, and DV versus the
suppression ratio duringMUSC sessions, all p’s> 0.2). If the drug
effects were due to spread to the basal nucleus we would expect
more ventral injection sites to have a stronger effect. If the drug
effects were due to spread to the central nucleus we would expect
more medial sites to have a stronger effect. Second, a previous
study that injected CCK-8 (an endogenous ligand of both CCK-1
and CCK-2 receptors) into the central nucleus of the amygdala
found that it produced generalized anxiety behavior (Belcheva
et al., 1994). In contrast, we observed no effect of PENT infu-
sions on pre-CS licking, only on CS-evoked suppression. This
is more consistent with the role of the LA than the role of the
central nucleus on expression of fear (Pare et al., 2004). Finally,
a study that used a similar volume of MUSC (0.2μL) to exam-
ine the roles of the LA and the central nucleus of the amygdala
in fear-conditioning conducted extensive controls to demonstrate
that there was no detectable spread of drug between the LA and
the central nucleus at that volume (for details see Wilensky et al.,
2006).
MEMORY RETRIEVAL VERSUS EXPRESSION OF BEHAVIOR?
The effect of MUSC infusions in the LA on lick suppression could
be interpreted in two ways. One interpretation is that activity in
the LA is required for the expression of lick suppression. The
second interpretation is that activity in the LA is required for
retrieval of the CS-US association. Although we cannot fully jus-
tify one interpretation over the other, we tend to favor the second
interpretation for the following reasons. Inactivation of the LA
with MUSC did not abolish lick suppression in response to the
footshock US (Figure 2C). This alone is not conclusive since foot-
shock is more intense than the CS. Thus, the difference between
suppression to the CS and the suppression to the US may be a
quantitative but not a qualitative difference. A second piece of
evidence is that MUSC inactivation of LA blocked the expression
of conditioned fear during the infusion session (Figure 2A), but
had no effect on the expression of conditioned fear in the fol-
lowing training session (Figure 4). If the conditioned fear had
been retrieved but the expression of fear blocked, then the atten-
uation of expression should have disrupted the reconsolidation
of the memory. This phenomena has been observed with the β-
adrenergic antagonist propranolol (De¸biec et al., 2011). As well,
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FIGURE 5 | Histological verification of cannula placements
in the LA. (A) Rats were implanted bilaterally with 22-gauge stainless
steel guide cannulae that terminated 1.5mm above the target location
in the LA. The target location coordinates, taken from Paxinos and Watson
(2004), were +5.7 anteroposterior, ±5.3 mediolateral, and +2.0mm
dorsoventral with reference to inter-aural zero. Locations of cannula tip
placements where infusions were delivered are indicated with
diamonds. Numbers indicate anterior-posterior distance(mm) from
inter-aural zero. (Dorsal LA – LAd; ventrolateral LA – LAvl; ventromedial
LA – Lavm). (B) Examples of Nissl stained sections used to construct A.
Modified from Paxinos and Watson (2004), with permission from
Elsevier© 2004.
several lines of evidence from the literature indicate that activity
in the LA encodes the CS-US association and activates multiple
downstream structures that control the various expressions of
fear. For example, active responses (like avoidance) and reactive
responses (like suppression or freezing) to fear can be dissoci-
ated with lesions of nuclei downstream from the LA (Killcross
et al., 1997; Amorapanth et al., 2000). Also, recording from the
LA in an aversive instrumental task, where an odor was paired
with quinine, demonstrated that negative odors elicited activity
in the LA even after the animal had learned to avoid the quinine
(Schoenbaum et al., 1999). Taken together, these findings favor
the conclusion that activity in the LA is related to retrieval or pro-
cessing of a CS and not linked to suppression or any other specific
expression of fear in general. Our study adds evidence that activ-
ity in the LA is required for the retrieval of the CS-US association
even when subjects are continually trained for weeks and when
the contingency between the CS and US is probabilistic.
MAINTENANCE OF FEAR
The finding that PENT infusions into the LA prolonged CS-
evoked lick suppression past the offset of the CS not only
implicates the LA in fear-memory retrieval, but also in the post-
retrieval maintenance of fear. Taken together, this suggests that
activation of the LA is necessary for a CS to evoke a fear-memory,
which in turn, triggers expression of fear and that de-activation
of the LA is required for the return to a baseline non-fearful state.
It has been proposed that the ability to recover quickly from an
initial fear reaction may be an important factor that contributes
to psychological resilience (Charney, 2004; Yehuda et al., 2006).
Conversely, the inability to recover from fear may be a risk factor
for an anxiety disorder such as PTSD. Interestingly, recent evi-
dence suggests that fear-reactivity and sustained fear recovery are
dissociable traits (Bush et al., 2007). Our current results suggest
that the LA is involved both in the retrieval of a fear memory and
in the short-term recovery from the same memory. Nonetheless,
different neural mechanisms may underlie these two aspects
of fear.
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